Research advances of(-)epigallo-catechingallate in cancer clinical trials
10.3969/j.issn.1000-8179.2018.02.523
- VernacularTitle:表没食子儿茶素没食子酸酯相关肿瘤临床试验研究进展
- Author:
Mengxia LEI
1
;
Dandan WANG
;
Fei YU
;
Xiaoying JIN
;
Xuesong CHEN
Author Information
1. 哈尔滨医科大学附属肿瘤医院内科 哈尔滨市150000
- Keywords:
(-)epigallo-catechingallate(EGCG);
tumor;
clinical trial;
safety
- From:
Chinese Journal of Clinical Oncology
2018;45(2):97-102
- CountryChina
- Language:Chinese
-
Abstract:
Epigallo-catechingallate(EGCG),the most abundant polyphenol and important active ingredient in green tea,is widely studied in cancer prevention and treatment.It has demonstrated various anti-cancer activities in vitro and in vivo,including induction of apoptosis, as well as inhibition of tumor cell invasion,migration,and angiogenesis.EGCG has been in the clinical stage of drug development with some findings currently available.In the present review,we systematically summarize the research advances of EGCG in cancer treatment through collection of global clinical trials and related results and discuss its safety,research efficacy,and critical challenges.
